GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Tianjin TEDA Biomedical Engineering Co Ltd (HKSE:08189) » Definitions » Cash-to-Debt

Tianjin TEDA Biomedical Engineering Co (HKSE:08189) Cash-to-Debt : 0.07 (As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Tianjin TEDA Biomedical Engineering Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Tianjin TEDA Biomedical Engineering Co's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.07.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Tianjin TEDA Biomedical Engineering Co couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Tianjin TEDA Biomedical Engineering Co's Cash-to-Debt or its related term are showing as below:

HKSE:08189' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07   Med: 0.66   Max: 2.35
Current: 0.07

During the past 13 years, Tianjin TEDA Biomedical Engineering Co's highest Cash to Debt Ratio was 2.35. The lowest was 0.07. And the median was 0.66.

HKSE:08189's Cash-to-Debt is ranked worse than
91.29% of 241 companies
in the Agriculture industry
Industry Median: 0.66 vs HKSE:08189: 0.07

Tianjin TEDA Biomedical Engineering Co Cash-to-Debt Historical Data

The historical data trend for Tianjin TEDA Biomedical Engineering Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Tianjin TEDA Biomedical Engineering Co Cash-to-Debt Chart

Tianjin TEDA Biomedical Engineering Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.67 0.65 0.33 0.09 0.07

Tianjin TEDA Biomedical Engineering Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 N/A 0.09 N/A 0.07

Competitive Comparison of Tianjin TEDA Biomedical Engineering Co's Cash-to-Debt

For the Agricultural Inputs subindustry, Tianjin TEDA Biomedical Engineering Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tianjin TEDA Biomedical Engineering Co's Cash-to-Debt Distribution in the Agriculture Industry

For the Agriculture industry and Basic Materials sector, Tianjin TEDA Biomedical Engineering Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Tianjin TEDA Biomedical Engineering Co's Cash-to-Debt falls into.



Tianjin TEDA Biomedical Engineering Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Tianjin TEDA Biomedical Engineering Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Tianjin TEDA Biomedical Engineering Co's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tianjin TEDA Biomedical Engineering Co  (HKSE:08189) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Tianjin TEDA Biomedical Engineering Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Tianjin TEDA Biomedical Engineering Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianjin TEDA Biomedical Engineering Co (HKSE:08189) Business Description

Traded in Other Exchanges
N/A
Address
No. 80, The 4th Avenue, 9th Floor, Block A2, Tianda Hi-Tech Park, TEDA Tianjin, Tianjin, CHN
Tianjin TEDA Biomedical Engineering Co Ltd is engaged in the research, development, and commercialization of biological compound fertilizers, medical and health products. It operates in two segments namely manufacturing and selling biological compound fertilizers and providing elderly care and health care services. The People's Republic of China is a primary geographical market for the company.
Executives
Long Ortiz 2101 Beneficial owner

Tianjin TEDA Biomedical Engineering Co (HKSE:08189) Headlines

No Headlines